Einfluss von Lebererkrankungen auf die Pharmakokinetik: Pathophysiologische Beurteilung und Leberfunktionstest

Direct measurement of hepatic blood flow requires specialized techniques that are often impractical in clinical settings. Instead, clinicians estimate hepatic function through patient examination and liver function tests, which provide more accessible and reliable information for assessing drug metabolism and clearance in patients with liver disease.

While the Child-Pugh and MELD scoring systems effectively categorize hepatic impairment severity, they do not directly correlate with drug pharmacokinetics. These scores assess liver function but don't reliably predict how drugs will be metabolized or cleared in hepatically impaired patients, necessitating additional assessment for dosing decisions.

Elevated AST/ALT ratios indicate acute liver injury, alcoholic hepatitis, or advanced liver fibrosis. These aminotransferase markers provide valuable insights into hepatic function and the liver's capacity to metabolize drugs, helping clinicians assess the degree of hepatic impairment and adjust medication dosing accordingly.

Increased alkaline phosphatase levels may indicate hepatic tumors or biliary obstruction, signaling potential compromise in liver function. This marker helps clinicians identify structural or metabolic abnormalities affecting the liver's ability to clear drugs and maintain functional capacity in patients requiring medication adjustments.

Prothrombin time deviations signal hepatic failure or biliary obstruction by reflecting the liver's synthetic function, while variations in urinary bilirubin levels help diagnose hepatobiliary disease. Together, these markers provide complementary information about liver dysfunction and guide effect of hepatic disease on pharmacokinetics dose adjustments due to hepatic impairment.

Chronic liver disease significantly compromises drug metabolism and clearance, requiring systematic dosing adjustments. Acute hepatitis causes more nuanced metabolic changes, necessitating case-by-case assessment. Both conditions demand tailored risk evaluation before dosing, though establishing standardized guidelines for hepatically impaired patients remains an evolving area of clinical practice.

Liver function tests measuring aminotransferases, alkaline phosphatase, bilirubin, and prothrombin time provide critical insights into hepatic function and drug clearance capacity. These markers enable clinicians to make informed decisions about tailored therapeutic interventions and medication adjustments, ensuring safe and effective treatment in patients with hepatic disease.